Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin vs Azole Prophylaxis in High-Risk Allogeneic HCT
NCT01503515Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Mar 2013
- Primary completion
- Dec 2019
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of caspofungin in invasive fungal infection (IFI), sponsored by Children's Oncology Group. Started Mar 2013; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT01503515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01503515.